Evidence map›Paper›PMID 41537152›Full record

ReviewRegenerative therapy2026

Mesenchymal stromal cell-derived extracellular vesicles in regenerative medicine: Standardisation, bioengineering and clinical translation.

Yusuke Shimizu, Yoshikazu Inoue, Naoki Matsuura, Tatsuya Ishii, Yoshihiro Sowa, Hiroshi Sunami, Edward Hosea Ntege

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yusuke ShimizuDepartment of Plastic and Reconstructive Surgery, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.
Yoshikazu InoueDepartment of Plastic and Reconstructive Surgery, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
Naoki MatsuuraDepartment of Plastic and Reconstructive Surgery, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.
Tatsuya IshiiDepartment of Plastic and Reconstructive Surgery, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.
Yoshihiro SowaDepartment of Plastic Surgery, School of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke-shi, Tochigi-ken, 329-049, Japan.
Hiroshi SunamiCenter for Advanced Medical Research, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.
Edward Hosea NtegeDepartment of Plastic and Reconstructive Surgery, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics that recapitulate key paracrine functions of MSCs whilst mitigating limitations of viable-cell therapies. Clinical translation is hindered by inconsistent dose metrics, lack of validated potency assays, and manufacturing complexities. Here we review advances in MSC-EV standardisation, source and culture determinants, engineering and delivery platforms, and clinical applications, exemplified by chronic wound healing. We operationalise dual-metric dosing (particles

Indexed as

Bioengineering and biomaterialsClinical translationDose metrics and potency assaysGMP manufacturing and comparabilityMesenchymal stromal cell–derived extracellular vesiclesPharmacokinetics and biodistribution

Identifiers

PMID41537152
PMCPMC12796862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.